Nanjing Medlander Medical Technology (SH:688273) Hua Yuan Zheng Quan·2025-03-16 09:37Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][35] Core Viewpoints - The report emphasizes the potential for accelerated growth in companies related to fertility support policies, with a strong recommendation for 麦澜德 (Milan) as a key player in this sector [3][11] - The industry is expected to benefit from a combination of innovation, international expansion, and an aging population, with a focus on identifying undervalued opportunities [24][36] Summary by Sections 1. Fertility Policies and Company Performance - Recent fertility policies are anticipated to boost the performance of related companies, particularly 麦澜德, which specializes in pelvic rehabilitation and postpartum recovery [11][17] - The report highlights a significant decline in birth rates, with 2023 figures showing a drop to 9.02 million births, necessitating government intervention through supportive policies [11][12] 2. Industry Perspective - The report outlines a strategic focus on innovation, international expansion, and addressing the needs of an aging population as the main themes for investment [24][36] - The pharmaceutical index has shown a 1.77% increase over the week, with notable individual stock performances, including 金城医药 (Jincheng Pharmaceutical) and 塞力医疗 (Saili Medical) [24][25] 3. Recommended Stocks - Key stocks to watch include 麦澜德, 一品红 (Yipinhong), and 健民集团 (Jianmin Group), among others, as they are positioned to benefit from the current market dynamics [40][36] - The report suggests a diversified approach, focusing on innovative pharmaceuticals, medical devices, and companies with strong international growth potential [36][38]